Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Undisclosed
Therapeutic Area : Nephrology
Study Phase : Preclinical
Sponsor : Novartis Pharmaceuticals Corporation
Deal Size : $230.0 million
Deal Type : Licensing Agreement
Details : Teijin will grant Novartis exclusive worldwide rights to research, develop, manufacture and commercialize an investigational small molecule candidate for proteinuric kidney diseases. The candidate is believed to impact the pathogenesis of multiple kidney...
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : $30.0 million
June 03, 2023
Lead Product(s) : Undisclosed
Therapeutic Area : Nephrology
Highest Development Status : Preclinical
Sponsor : Novartis Pharmaceuticals Corporation
Deal Size : $230.0 million
Deal Type : Licensing Agreement
Lead Product(s) : Incobotulinumtoxin A
Therapeutic Area : Neurology
Study Phase : Approved FDF
Sponsor : Merz Pharma
Deal Size : Inapplicable
Deal Type : Inapplicable
Teijin Receives Additional Approval in Japan for Botulinum Toxin Type A Xeomin ® From Merz
Details : Xeomin ® is effective in the treatment of peripheral cholinergic nerve endings by decreasing the contraction of voluntary muscles, and relieves muscle tone by inhibiting the release of a neurotransmitter, acetylcholine.
Product Name : Xeomin
Product Type : Protein
Upfront Cash : Inapplicable
June 23, 2021
Lead Product(s) : Incobotulinumtoxin A
Therapeutic Area : Neurology
Highest Development Status : Approved FDF
Sponsor : Merz Pharma
Deal Size : Inapplicable
Deal Type : Inapplicable
Teijin Pharma and TransThera Biosciences Form Strategic R&D Collaboration
Details : Teijin Pharma and TransThera will establish a joint drug discovery collaboration of multiple drug targets with the immediate goal of acquiring compounds as candidates for new drug development based on the targets and compounds found by Teijin Pharma.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
December 18, 2020